Proteomic cancer biomarkers from discovery to approval: It's worth the effort

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 135-136

  Li, Danni ^a   Chan, Daniel W ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; cancer; IVDMIA; OVA1; proteomics

Indexed keywords

TUMOR MARKER; PROTEOME;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGAL ASPECT; PATIENT CARE; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; STUDY DESIGN; NEOPLASMS; PROGNOSIS;

HUMANS; NEOPLASMS; PROGNOSIS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896977252     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.897614     Document Type: Review

References (5)

1. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16): 5882-90
2. Hellstro?m I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63(13):3695-700
3. Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710-14
4. Wang M, Valenzuela L, Murphy G, Chu T. Purification of a human prostate specific antigen. Invest Urol 1979;17(2): 159-63
5. Zhang Z. An in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: harvesting the power of multiple biomarkers. Rev Obstet Gynecol 2012;5(1):35